Citation Information :
Samprathi A, Samprathi M, Reddy M. Presepsin: Hope in the Quest for the Holy Grail. Indian J Crit Care Med 2022; 26 (6):664-666.
Global sepsis alliance. Available from: https://www.global-sepsis-alliance.org/sepsis#:~:text=Sepsis%20is% 20a%20global%20health,the%20rest%20of%20their%20lives.
Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: World Health Organization; 2020.
Cassini A, Fleischmann-Struzek C, Naghavi M, Reinhart K, Allegranzi B. WHO Sepsis Expert Technical Group. Future directions and priorities in sepsis epidemiology research: a call for action. Bull World Health Organ 2021;99(5):398–401. DOI: 10.2471/BLT.20.276709.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287.
Cervellin G, Schuetz P, Lippi G. Toward a holistic approach for diagnosing sepsis in the emergency department. Adv Clin Chem 2019;92:201–216. DOI: 10.1016/bs.acc.2019.04.004.
Oikonomakou MZ, Gkentzi D, Gogos C, Akinosoglou K. Biomarkers in pediatric sepsis: a review of recent literature. Biomark Med 2020;14(10):895–917. DOI: 10.2217/bmm-2020-0016.
Lanziotti VS, Póvoa P, Soares M, Silva JR, Barbosa AP, Salluh JI. Use of biomarkers in pediatric sepsis: literature review. Rev Bras Ter Intensiva 2016;28(4):472–482. DOI: 10.5935/0103-507X.20160080.
Wen MY, Huang LQ, Yang F, Ye JK, Cai GX, Li XS, et al. Presepsin level in predicting patients’ in-hospital mortality from sepsis under sepsis-3 criteria. Ther Clin Risk Manag 2019;15:733–739. DOI: 10.2147/TCRM.S209710.
Drăgoescu AN, Pădureanu V, Stănculescu AD, Chiuțu LC, Florescu DN, Gheonea IA, et al. Presepsin as a potential prognostic marker for sepsis according to actual practice guidelines. J Pers Med 2020;11(1):2. DOI: 10.3390/jpm11010002.
Wu CC, Lan HM, Han ST, Chaou CH, Yeh CF, Liu SH, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. Ann Intensive Care 2017;7(1):91. DOI: 10.1186/s13613-017-0316-z.
Yang HS, Hur M, Yi A, Kim H, Lee S, Kim SN. Prognostic value of presepsin in adult patients with sepsis: systematic review and meta-analysis, PLoS One 2018;13(1):e0191486. DOI: 10.1371/journal.pone.0191486.
Yoon SH, Kim EH, Kim HY, Ahn JG. Presepsin as a diagnostic marker of sepsis in children and adolescents: a systemic review and meta-analysis. BMC Infect Dis 2019;19(1):760. DOI: 10.1186/s12879-019-4397-1.
Bamba Y, Moro H, Aoki N, Koizumi T, Ohshima Y, Watanabe S, et al. Increased presepsin levels are associated with the severity of fungal bloodstream infections. PLoS One 2018;13:e0206089. DOI: 10.1371/journal.pone.0206089.
Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med 2015;41(1):12–20. DOI: 10.1007/s00134-014-3514-2.
Park M, Hur M, Kim H, Lee CH, Lee JH, Kim HK, et al. Prognostic utility of procalcitonin, presepsin, and the VACO index for predicting 30-day mortality in hospitalized COVID-19 patients. Ann Lab Med 2022;42(4):406–414. PMID: 35177561.
Yamamoto T, Nishimura T, Kaga S, Uchida K, Tachibana Y, Esaki M, et al. Diagnostic accuracy of presepsin for sepsis by the new Sepsis-3 definitions. Am J Emerg Med 2019;37(10):1936–1941. DOI: 10.1016/j.ajem.2019.01.025.
Chen M, Lu X, Hu L, Liu P, Zhao W, Yan H, et al. Development and validation of a mortality risk model for pediatric sepsis. Medicine (Baltimore) 2017;96(20):e6923. DOI: 10.1097/MD.0000000000006923.
Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Pediatric sepsis biomarker risk model-II: redefining the pediatric sepsis biomarker risk model with septic shock phenotype. Crit Care Med 2016;44(11):2010–2017. DOI: 10.1097/CCM.0000000000001852.
Wong HR, Weiss SL, Giuliano JS, Wainwright MS, Cvijanovich NZ, Thomas NJ, et al. Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS One 2014;9(1):e86242. DOI: 10.1371/journal.pone.0086242.
Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Prospective testing and redesign of a temporal biomarker based risk model for patients with septic shock: implications for septic shock biology. E Bio Med 2015;2(12):2087–2093. DOI: 10.1016/j.ebiom.2015.11.035.
Hur M, Kim H, Lee S, Cristofano F, Magrini L, Marino R, et al. Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis. BMC Infect Dis 2014;14:224. DOI: 10.1186/1471-2334-14-224.
Osler W. The evolution of modern medicine, 219. New Haven, CT, USA: New Haven Yale University Press, 1921. p. 60.
Khera D, Toteja N, Singh S, Singh S, Kumar P, Sharma P, et al. Is There a Role of Presepsin as a Novel Biomarker in Pediatric Sepsis? Indian J Crit Care Med 2022;26(6):712–716.